Header Logo

Connection

DONALD YEE to Infant

Back to Details
This is a "connection" page, showing publications DONALD YEE has written about Infant.
DONALD YEE
Connection Strength
0.350
Infant
  1. Population Pharmacokinetics of Enoxaparin in Pediatric Patients. Ann Pharmacother. 2018 02; 52(2):140-146.
    View in: PubMed
    Score: 0.045
  2. Population pharmacokinetics of human antithrombin concentrate in paediatric patients. Br J Clin Pharmacol. 2017 Nov; 83(11):2450-2457.
    View in: PubMed
    Score: 0.044
  3. Antithrombin Concentrate Use in Children Receiving Unfractionated Heparin for Acute Thrombosis. J Pediatr. 2015 Sep; 167(3):645-9.
    View in: PubMed
    Score: 0.038
  4. Focus on diagnosis: a primer on D-dimer. Pediatr Rev. 2011 Jan; 32(1):31-3.
    View in: PubMed
    Score: 0.028
  5. Varied opinions on thrombolysis for venous thromboembolism in infants and children: findings from a survey of pediatric hematology-oncology specialists. Pediatr Blood Cancer. 2009 Dec; 53(6):960-6.
    View in: PubMed
    Score: 0.026
  6. Ornithine transcarbamylase deficiency: a possible risk factor for thrombosis. Pediatr Blood Cancer. 2009 Jul; 53(1):100-2.
    View in: PubMed
    Score: 0.025
  7. Acquired von Willebrand syndrome and Wilms tumor: not always benign. Pediatr Blood Cancer. 2009 Mar; 52(3):392-4.
    View in: PubMed
    Score: 0.025
  8. Thromboelastographic and hemostatic characteristics in pediatric patients with sickle cell disease. Arch Pathol Lab Med. 2005 Jun; 129(6):760-5.
    View in: PubMed
    Score: 0.019
  9. Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial. Lancet Haematol. 2020 Jan; 7(1):e18-e27.
    View in: PubMed
    Score: 0.013
  10. PREVAPIX-ALL: Apixaban Compared to Standard of Care for Prevention of Venous Thrombosis in Paediatric Acute Lymphoblastic Leukaemia (ALL)-Rationale and Design. Thromb Haemost. 2019 May; 119(5):844-853.
    View in: PubMed
    Score: 0.012
  11. Enoxaparin Population Pharmacokinetics in the First Year of Life. Ther Drug Monit. 2017 12; 39(6):632-639.
    View in: PubMed
    Score: 0.011
  12. Safety and efficacy of a glycoPEGylated rFVIII (turoctocog alpha pegol, N8-GP) in paediatric patients with severe haemophilia A. Thromb Haemost. 2017 08 30; 117(9):1705-1713.
    View in: PubMed
    Score: 0.011
  13. Association of outcomes and anti-Xa levels in the treatment of pediatric venous thromboembolism. Pediatr Blood Cancer. 2017 Nov; 64(11).
    View in: PubMed
    Score: 0.011
  14. Pediatric Acquired von Willebrand Syndrome in Cardiopulmonary Disorders: Do Laboratory Abnormalities Predict Bleeding Risk? J Pediatr Hematol Oncol. 2017 03; 39(2):121-125.
    View in: PubMed
    Score: 0.011
  15. Improving evidence on anticoagulant therapies for venous thromboembolism in children: key challenges and opportunities. Blood. 2015 Dec 10; 126(24):2541-7.
    View in: PubMed
    Score: 0.010
  16. Age-related differences in urinary 11-dehydroxythromboxane B2 between infants, children, and adolescents: another example of developmental hemostasis? Pediatr Blood Cancer. 2014 Nov; 61(11):2074-6.
    View in: PubMed
    Score: 0.009
  17. FondaKIDS: a prospective pharmacokinetic and safety study of fondaparinux in children between 1 and 18 years of age. Pediatr Blood Cancer. 2011 Dec 01; 57(6):1049-54.
    View in: PubMed
    Score: 0.007
  18. Case series of thrombotic thrombocytopenic purpura in children and adolescents. J Pediatr Hematol Oncol. 2003 Apr; 25(4):336-9.
    View in: PubMed
    Score: 0.004
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.